Longeveron Mesenchymal Stem Cells ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 211 | Hypoplastic left heart syndrome | 1 |
211. Hypoplastic left heart syndrome
Clinical trials : 21 / Drugs : 29 - (DrugBank : 9) / Drug target genes : 5 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03525418 (ClinicalTrials.gov) | February 21, 2018 | 19/2/2018 | Lomecel-B Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) | Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS) | HLHS | Biological: Longeveron Mesenchymal Stem Cells | Longeveron Inc. | NULL | Completed | N/A | 1 Year | All | 10 | Phase 1/Phase 2 | United States |